Transplant Surgery Research Laboratory and Division of Transplant Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Department of General, Visceral and Transplant Surgery, Tuebingen University Hospital, Tuebingen, Germany.
Transplantation. 2018 Jan;102(1):59-69. doi: 10.1097/TP.0000000000001902.
Although the elderly represents a rapidly growing population among transplant recipients, age-specific aspects have not been considered sufficiently in clinical trials. Moreover, age-specific effects of immunosuppressive therapies remain poorly understood.
Here, we assessed the impact of rapamycin on alloimmune responses in old recipients using a fully major histocompatibility complex-mismatched murine transplantation model.
Old untreated recipients displayed a prolonged skin graft survival compared to their young counterparts, an observation that confirmed data of our previous experiments. Rapamycin led to a significant prolongation of graft survival in both young and old recipients. However, graft survival was age-dependent and extended in old versus young recipients (19 days vs 12 days, P = 0.004). This age-specific effect was not linked to changes in frequencies or subset composition of either cluster of differentiation (CD)8 or CD4 T cells. Moreover, antiproliferative effects of rapamycin on CD8 and CD4 T cells as assessed by in vivo bromdesoxyuridine incorporation were comparable and age-independent. In contrast, the systemic production of IL-10 was markedly elevated in old recipients treated with rapamycin. In parallel to this shift in cytokine balance, IFN-γ/IL-10 double-positive regulatory type 1 cells emerged during T helper type 1 differentiation of old T helper cells in presence of rapamycin. Similarly, CD4IFN-γIL-10 cells expanded among Foxp3-negative cells after in vivo treatment of old recipients with rapamycin.
Our results highlight novel aspects of age-dependent immunosuppressive effects of rapamycin, with relevance for age-specific immunosuppressive regimens.
尽管老年人在移植受者中是一个快速增长的群体,但在临床试验中尚未充分考虑到年龄特异性方面。此外,免疫抑制治疗的年龄特异性影响仍知之甚少。
在这里,我们使用完全主要组织相容性复合物错配的小鼠移植模型评估了雷帕霉素对老年受者同种免疫反应的影响。
未经治疗的老年受者的皮肤移植物存活时间比年轻受者延长,这一观察结果证实了我们之前实验的数据。雷帕霉素在年轻和老年受者中均导致移植物存活时间显著延长。然而,移植物存活时间是年龄依赖性的,并在老年受者中延长(19 天 vs 12 天,P = 0.004)。这种年龄特异性效应与 CD8 和 CD4 T 细胞的簇分化(CD)8 或 CD4 T 细胞的频率或亚群组成的变化无关。此外,通过体内溴脱氧尿苷掺入评估的雷帕霉素对 CD8 和 CD4 T 细胞的抗增殖作用是可比的且与年龄无关。相比之下,在接受雷帕霉素治疗的老年受者中,IL-10 的全身产生明显升高。与细胞因子平衡的这种转变平行,在雷帕霉素存在下,老年 T 辅助细胞的 T 辅助 1 分化过程中出现了 IFN-γ/IL-10 双阳性调节 T 细胞 1 型。同样,在体内用雷帕霉素治疗老年受者后,Foxp3 阴性细胞中 CD4IFN-γIL-10 细胞扩增。
我们的结果突出了雷帕霉素的年龄依赖性免疫抑制作用的新方面,这与年龄特异性免疫抑制方案有关。